Peking University Institute of Cardiovascular Sciences
Yan Zhang
Zhang Yan, Researcher / Tenured Associate Professor
Contact Information
Research Direction
Mainly engaged in cardiovascular physiology and pathophysiology research, focusing on the mechanisms of cardiomyocyte injury and protection.
Biography
Zhang Yan is a Researcher/Tenured Associate Professor at the Institute of Cardiovascular Sciences, Peking University, a Principal Investigator at the National Key Laboratory of Vascular Homeostasis and Remodeling, a Peking University Boya Distinguished Professor, and a Doctoral Supervisor. He is a recipient of the National Science Fund for Distinguished Young Scholars and was selected for the National Ten Thousand Talents Program - Young Top-notch Talent. He obtained his Bachelor of Clinical Medicine and Ph.D. in Physiology from Peking University Health Science Center. His research primarily focuses on cardiovascular physiology and pathophysiology, specifically the mechanisms of cardiomyocyte injury and protection. As a project leader, he has received 5 grants from the National Natural Science Foundation of China and 1 sub-project from the National Key R&D Program of the Ministry of Science and Technology. He has published 54 papers, including 27 as first author or corresponding author, in journals such as Nature , Cell , Nature Medicine , Nature Cell Biology , and Circulation . He is an inventor on 9 authorized national invention patents. He currently holds several positions, including Council Member of the Chinese Association for Physiological Sciences, Committee Member of the Vascular Medicine Committee of the Chinese Association of Pathophysiology and Deputy Head of the Youth Working Group, Youth Committee Member of the Receptor Committee of the Chinese Association of Pathophysiology, Committee Member of the Aging Genetics Branch of the Chinese Society of Genetics, Standing Committee Member of the Geriatrics Branch of the China Association of Gerontology and Geriatrics, Deputy Director of the Blood Pressure Prevention and Research Professional Committee of the China Human Health Science and Technology Promotion Association, and Standing Committee Member of the Geriatrics Professional Committee of the Cross-Strait Medical and Health Exchange Association.
Education/Work Experience
Education:
2003/9 -- 2008/7 Peking University Health Science Center, Physiology, Ph.D. (Supervisor: Prof. Rui-Ping Xiao)
1998/9 -- 2003/7 Peking University Health Science Center, Clinical Medicine, Bachelor
Work Experience:
2020/10 -- Present Peking University, Institute of Cardiovascular Sciences, Researcher
2010/10 -- 2020/9 Peking University, Institute of Molecular Medicine, Associate Researcher
2008/10 -- 2010/9 Peking University, Institute of Molecular Medicine, Postdoctoral Fellow
2005/10 -- 2007/10 University of Medicine and Dentistry of New Jersey, USA, Postdoctoral Fellow
Research Achievements (Grants, Publications, etc.)
Representative Publications:
1. Hu Q, Zhang J, Luo X, Hu P, Li J, Li F, Wang Z, Zhang S, Jiao Z, Liu Y, Duanmu J, Jin L, Xie P, Zhu W, Zheng W, Shang H, Hu X, Chen Z, Xiao RP, Zhang Y*. Intracellular L-PGDS-derived 15d-PGJ2 inhibits CaMKII through lipoxidation to alleviate cardiac ischemia/reperfusion injury. Circulation. 2025, 152, 41-57. (*Corresponding author, Impact Factor: 38.6).
2. Zhang J^#^, Zhao C^#^, Zhang W^#^, Zhang M^#^, Li F, Shang H, Zheng W, Li Y, Quan L, Li X, Li H, Wang L, Zheng W, Zhou Yi, D W Wang*, Dong E*, Chen C*, Zhang Y*. Danhong Injection targets CaMKII through Dihydrotanshinone I to alleviate cardiomyocyte death and inflammation in viral myocarditis. Sci China Life Sci. 2025, online first. (*Co-corresponding author, Impact Factor: 9.5).
3. Zhang W^#^, Zhang J^#^, Wang Z^#^, Li T^#^, Liu C, Kang X, Cui X, Yang J, Qu H, Duanmu J, Peng Y, Wang K, Jin L, Xie P, Zheng W, Shang H, Liu Y, Tian Z, Liu Z, Jin Y, Li Y, Li N, Zhuo X, Wu Y, Shi X, Ma R, Sun Y, Zhang K, Fang X, Hu X*, Dong E*, Zhang S*, Zhang Y^†^. Extracellular RIPK3 Acts as a Danger-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury. Circulation. 2024, 150, 1791-1811. (^†^Senior author, Impact Factor: 38.6).
4. Wang WW^#^, Ji SY^#^, Zhang W^#^, Zhang J^#^, Cai C^#^, Hu R^#^, Zang SK, Miao L, Xu H, Chen LN, Yang Z, Guo J, Qin J, Shen DD, Liang P, Zhang Y*, Zhang Y*. Structure-based design of non-hypertrophic apelin receptor modulator. Cell. 2024, 187, 1460-1475. (*Co-corresponding author, Impact Factor: 42.5).
5. Lu S, Cao C, Zhang W, Li J, Yang J, Huang Z, Wu Z, Liu B, Huang H, Wang H, Wang Y, Liu D, Zhang Z, Liu K, Yang G, Gong X, Dai H, Li Y, Dong E*, Zhang X*, Zhang Y*. Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling. Sci China Life Sci. 2025, 68, 593-609. (*Co-corresponding author, Impact Factor: 9.5).
6. Wu Z^#^, Shi Y^#^, Cui Y, Xing X, Zhang L, Liu D, Zhang Y, Dong J, Jin L, Pang M, Xiao RP, Zhu Z, Xiong JW, Tong X, Zhang Y*, Wang S*, Tang F*, Zhang B*. Single-cell analysis reveals an Angpt4-initiated EPDC-EC-CM cellular coordination cascade during heart regeneration. Protein Cell. 2023, 14, 350-368. (*Co-corresponding author, Impact Factor: 12.8).
7. Dong H^#^, Zhang Y^#^, Sun D, Wang G, Zhang Q, Hidru TH, Yang Y, Wang S, Wei Y, Liu F, Zhang J, Xia Y*, Yang X*. Refining prediction of stroke in sinus node dysfunction patients without atrial fibrillation using a P-combined score: a multi-centre study. Eur J Prev Cardiol. 2023, 21, 507-518. (*Co-first author, Impact Factor: 7.5).
8. Zhang J, Liang R, Wang K, Zhang W, Zhang M, Jin L, Xie P, Zheng W, Shang H, Hu Q, Li J, Chen G, Wu F, Lan F, Wang L, Wang S.Q., Li Y, Zhang Y, Liu J, Lv F, Hu X, Xiao R.P., Lei X*, Zhang Y*. Novel CaMKII-δ inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth. Circulation . 2022, 145, 1154-1168. (*Co-corresponding author, Impact Factor: 38.6).
9. Yao Y^#^, Li F^#^, Zhang M^#^, Jin L, Xie P, Liu D, Zhang J, Hu X, Lv F, Shang H, Zheng W, Sun X, Duanmu J, Wu F, Lan F, Xiao RP., Zhang Y*. Targeting CaMKII-δ9 Ameliorates Cardiac Ischemia/reperfusion Injury by Inhibiting Myocardial Inflammation. Circ Res . 2022, 130, 887-903. (*Corresponding author, Impact Factor: 16.2).
10. Feng H^#^, Shen H^#^, Robeson MJ, Wu YH, Wu HK., Chen GJ, Zhang S, Xie P, Jin L, He Y, Wang Y, Lv F, Hu X, Zhang Y*, Xiao RP. *. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage. Diabetes. 2022, 71, 298-314. (*Co-corresponding author, Impact Factor: 7.5).
11. Song Y, Xu C, Liu J, Li Y, Wang H, Shan D, Wainer I, Hu X, Zhang Y*, Woo YH*, Xiao RP. Heterodimerization with 5-HT2BR is indispensable for β2AR-mediated cardioprotection. Circ Res . 2021, 128, 262-277 (*Co-corresponding author, Impact Factor: 16.2).
12. Shan D^#^, Guo S^#^, Wu HK, Lv F, Jin L, Zhang M, Xie P, Wang Y, Song Y, Wu F, Lan F, Hu X, Cao CM*, Zhang Y*, Xiao RP*. Cardiac ischemic preconditioning promotes MG53 secretion through H~2~O~2~-activated PKC-δ signaling. Circulation . 2020, 142, 1077-1091 (*Co-corresponding author, Impact Factor: 38.6).
13. Zhang M, Gao H, Liu D, Zhong X, Shi X, Yu P, Jin L, Liu Y, Tang Y, Song Y, Liu J, Hu X, Li CY, Song L, Qin J, Wu F, Lan F, Zhang Y*, Xiao RP. CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair. Nat Cell Biol . 2019, 21, 1152-1163 (*Corresponding author, Impact Factor: 19.1).
14. Wu HK^#^, Zhang Y^#^, Cao CM^#^, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, Song R, Peng W, Liu F, Guo J, Tang L, He Y, Shan D, Huang J, Zhou Z, Wang D, Lv F*, Xiao RP*. Glucose-sensitive myokine/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis. Circulation . 2019, 139, 901-914 (^#^Co-first author, Impact Factor: 38.6).
15. Wang Y, Jin L, Song Y, Zhang M, Shan D, Liu Y, Lv F, Xiao RP, Zhang Y*. β-arrestin 2 mediates cardiac ischemia-reperfusion injury via inhibiting GPCR-independent cell survival signaling. Cardiovasc Res. 2017, 113, 1615-1626 (*Corresponding author, Impact Factor: 13.3).
16. Zhang T^#^, Zhang Y^#^*, Cui M, Jin L, Wang Y, Lv F, Liu Y, Zheng W, Shang H, Zhang J, Zhang M, Wu HK, Guo J, Zhang X, Hu X, Cao CM, Xiao RP*. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 2016, 22, 175-182 (*Co-corresponding author,^#^Co-first author, Impact Factor: 50.0).
17. Zhu W^#^, Tsang S^#^, Browe, DM^#^, Woo AY, Huang Y, Xu C, Liu JF, Lv F, Zhang Y*, Xiao RP*. Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling. JCI Insight. 2016, 1, e84969 (*Co-corresponding author, Impact Factor: 6.1).
18. Song RS^#^, Peng W^#^, Zhang Y^#^, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, Zhang M, Jiang P, Liu F, Meng S, Zhang X, Jiang P, Cao CM*, Xiao RP*. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature. 2013, 494, 375-379 (^#^Co-first author, Impact Factor: 48.5).
19. Zhang Y^#^, Lv F^#^, Jin L, Peng W, Song RS, Ma J, Cao CM*, Xiao RP*. MG53 participates in ischaemic postconditioning through the RISK signaling pathway. Cardiovasc Res . 2011, 91, 108-115 (^#^Co-first author, Impact Factor: 13.3).
20. Cao CM^#^, Zhang Y^#^, Weisleder N^#^, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J*, Xiao RP*. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation . 2010, 121, 2565-2574 (^#^Co-first author, Impact Factor: 38.6).
21. Peng W^#^, Zhang Y^#^, Zheng M, Cheng H, Zhu W, Cao CM*, Xiao RP*. Cardioprotection by CaMKII-δB is mediated by phosphorylation of HSF1 and subsequent expression of inducible HSP70. Circ Res . 2010, 106, 102-110 (^#^Co-first author, Impact Factor: 16.2).